Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Cancer becomes far more dangerous when it spreads from its original location to other parts of the body. This process is ...
The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment ...
Non-small cell lung cancer (NSCLC) remains a predominant cause of cancer-related mortality worldwide. In recent years, immune ...
Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data ...
Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that ...
A new clinical trial is enrolling up to 60 children and young people with solid tumors across the United States and United ...
Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...
Neoadjuvant or perioperative immunotherapy, either alone or in combination with other antineoplastic agents (e.g., chemotherapy), has been shown to improve ...
WashU Medicine researchers have described how mRNA cancer vaccines engage the immune system, through an unconventional pathway involving two subsets of immune cells called dendritic cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results